Advanced imaging techniques including whole-body magnetic resonance imaging (WBMRI) and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) are now recommended by the 2016 National Institute for Health and Care Excellence and the 2017 British Society of Haematology guidelines for patients with newly diagnosed myeloma and plasmacytoma due to their superiority in the detection of bone disease. The detection of greater than one unequivocal bone lesion on MRI (> 5 mm) is a myeloma-defining event. There are however many unanswered questions regarding the utility of WBMRI and 18F-FDG PET/CT in myeloma assessment, including diagnostic performance of WBMRI versus 18F-FDG PET/CT in baseline staging and response assessment; the accuracy and feasibility of WBMRI in disease quantitation using currently available software platforms; and the validity and clinical role of potential imaging biomarkers such as apparent diffusion co-efficient (ADC) and standardised uptake value (SUV), and their correlation with clinical assessment. There is also little available literature regarding the possible role of hybrid techniques such as whole body 18F-FDG PET/MRI in myeloma.
| Date of Award | 1 Oct 2021 |
|---|
| Original language | English |
|---|
| Awarding Institution | |
|---|
| Supervisor | Vicky Goh (Supervisor) & Gary Cook (Supervisor) |
|---|
Advanced imaging assessment of myeloma with whole-body magnetic resonance imaging and 18F-Fluorodeoxyglucose positron emission tomography/magnetic resonance imaging
Westerland, O. (Author). 1 Oct 2021
Student thesis: Doctoral Thesis › Doctor of Medicine by Research